chr1-179551361-G-A
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_014625.4(NPHS2):c.964C>T(p.Arg322Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000124 in 1,613,992 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. R322R) has been classified as Likely benign.
Frequency
Consequence
NM_014625.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NPHS2 | NM_014625.4 | c.964C>T | p.Arg322Ter | stop_gained | 8/8 | ENST00000367615.9 | |
AXDND1 | NM_144696.6 | c.3032-3151G>A | intron_variant | ENST00000367618.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NPHS2 | ENST00000367615.9 | c.964C>T | p.Arg322Ter | stop_gained | 8/8 | 1 | NM_014625.4 | P1 | |
AXDND1 | ENST00000367618.8 | c.3032-3151G>A | intron_variant | 1 | NM_144696.6 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152146Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251050Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135638
GnomAD4 exome AF: 0.0000116 AC: 17AN: 1461846Hom.: 0 Cov.: 43 AF XY: 0.0000193 AC XY: 14AN XY: 727222
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152146Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74314
ClinVar
Submissions by phenotype
Nephrotic syndrome, type 2 Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 30, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Nov 14, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 20, 2023 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 02, 2022 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the NPHS2 protein in which other variant(s) (p.Phe344Leufs*4) have been determined to be pathogenic (PMID: 23515051, 29660491; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 371673). This premature translational stop signal has been observed in individual(s) with steroid-resistant nephrotic syndrome (PMID: 15253708). This variant is present in population databases (rs763818901, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Arg322*) in the NPHS2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 62 amino acid(s) of the NPHS2 protein. - |
Idiopathic nephrotic syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 09, 2023 | Variant summary: NPHS2 c.964C>T (p.Arg322X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been associated with Nephrotic Syndrome in HGMD. The variant allele was found at a frequency of 4e-06 in 251370 control chromosomes. c.964C>T has been reported in the literature in one individual affected with sporadic steroid-resistant nephrotic syndrome (Weber_2004). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (n=2) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at